Metastatic Non-small Cell Lung Cancer Clinical Trial
Official title:
A Phase 1b/2 Trial of Dupilumab Given in Conjunction With PD-1 or PD-L1 Blockade in the Treatment of Relapsed/Refractory Metastatic NSCLC
This is an Phase Ib/2 study, single arm, single cohort study to determine the safety and tolerability of Dupilumab with PD-(L)1 blockade for patients with relapsed/refractory metastatic NSCLC. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1 blocking agents in patients with relapsed/refractory NSCLC, who have progressed on prior PD-(L)1 agents
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05985330 -
Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT05984277 -
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
|
Phase 3 | |
| Completed |
NCT03215810 -
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT05675683 -
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
|
||
| Active, not recruiting |
NCT02411448 -
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
|
Phase 3 | |
| Recruiting |
NCT04410796 -
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
|
Phase 2 | |
| Recruiting |
NCT06343402 -
Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03300115 -
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
|
Phase 2 | |
| Recruiting |
NCT05635708 -
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT03265080 -
A Study of ADXS-NEO Expressing Personalized Tumor Antigens
|
Phase 1 | |
| Active, not recruiting |
NCT05226598 -
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
|
Phase 3 | |
| Withdrawn |
NCT02639234 -
Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05364073 -
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
|
Phase 1 | |
| Completed |
NCT03926260 -
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA
|
N/A | |
| Active, not recruiting |
NCT03976375 -
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
|
Phase 3 | |
| Recruiting |
NCT05546905 -
A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
|
||
| Withdrawn |
NCT01936961 -
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
|
N/A | |
| Not yet recruiting |
NCT06428422 -
The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT06212752 -
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
|
Phase 3 |